Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA‐B) genotype and allopurinol dosing: 2015 update
Clinical Pharmacology & Therapeutics2015Vol. 99(1), pp. 36–37
Citations Over TimeTop 1% of 2015 papers
Yoshiro Saito, L. Dudley Stamp, KE Caudle, MS Hershfield, Ellen M. McDonagh, J. Callaghan, Wichittra Tassaneeyakul, Taisei Mushiroda, Naoyuki Kamatani, BR Goldspiel, EJ Phillips, Teri E. Klein, M.T.M. Lee
Abstract
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).
Related Papers
- → Impaired response or insufficient dosage?—Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout(2014)62 cited
- → Allopurinol: insights from studies of dose–response relationships(2016)31 cited
- → What Is Allopurinol Failure and What Should We Do About It?(2024)4 cited
- [Therapeutic efficacy of slow-release allopurinol in gout and hyperuricaemia (author's transl)].(1981)
- 흰쥐에 사염화탄소 투여시 간 Xanthine Oxidase 활성에 미치는 Allopurinol의 영향(1995)